The table below shows NOVAVAX INC's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$1.12B
$682.16M
$983.71M
$1.98B
$1.15B
$475.60M
Cost of revenue
$73.04M
$202.74M
$343.77M
$902.64M
$0.00
$0.00
Gross profit
-
-
-
-
-
-
R&D
$342.32M
$391.17M
$737.50M
$1.24B
$2.53B
$747.03M
SG&A
NVAX annual revenue (10-K history)
NOVAVAX INC reported annual revenue of $1.12B for fiscal year 2025. That is up 64.7% from $682.16M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $15.35M (FY 2016) to $1.12B. Figures come from the company's audited annual reports as filed with the SEC.
